drugset / Trial / NCT02342067

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

NCT02342067

Phase 1 Completed 20 enrolled Tobira Therapeutics, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate the PK of PGZ administered with and without CVC.

Timeline

Start
2014-12
Primary completion
2015-03
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenicriviroc Small molecule 150 mg
Subject Pioglitazone Small molecule 45 mg

Indications

No indication recorded.